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Money, Meet Mouth:
The Era of Regulation and Prescription
Drug Importation/Reimportation
Aaron Jones Wong*

I. Introduction

The complexity
of importation
and reimportation
of prescription
drugs cannot be
understated, as it
is both a national
and international
issue involving
economics, public
policy, private
industry, intellectual
property, and
criminal law.

Health care is an industry unlike any other. It is
comprised of both goods and services like many other
commercial industries, including the agriculture, airline,
and housing industries. It is a necessity for survival in
terms of preventative medicine, pharmaceutical drugs,
or life-saving procedures, and a luxury for those who
can afford often-expensive cosmetic procedures or
medical devices. Like any other commercial industry
in our free market society, it requires regulation and
licensing to protect people from counterfeits, poor
quality, and deliberate contamination. Why are we as a
society so unwilling to devote the necessary resources
to devise and implement quality control measures in
an industry like health care, where quality services
and pharmaceuticals are the only means of survival for
millions of Americans?
The complexity of importation and reimportation of
prescription drugs cannot be understated, as it is both a
national and international issue involving economics,
public policy, private industry, intellectual property,
and criminal law. This paper explores why our country
has failed to devote the necessary resources to health
care, and in particular prescription drug importation
and reimportation, in an economic and legal context.
It analyzes the unique market characteristics of
the pharmaceutical industry, the framework of
pharmaceutical drug regulation including prescription
drug importation, and the regulatory structure of
importation in general. Part II provides background on
the health care industry and prescription drug markets
in the U.S. and abroad. Part III examines legislative
proposals for drug importation and reimportation
and the controversial congressional reaction to
rising prescription drug prices in the U.S. Part IV
addresses counterarguments primarily put forth by
pharmaceutical companies and the U.S. Food and
Drug Administration (FDA), against drug importation
and reimportation. Part V discusses a variety of laws
and regulations pertaining to the cross border flow
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of goods, services, and people into the U.S. Part VI
suggests methods of reform. Part VII concludes
that, regardless of whether legalized importation is
the answer, safety inadequacies in the regulation of
imported drugs must be improved.

II. Health Care and Prescription Drugs:
Rising Cost
A. The Current Landscape of Health Care Spending in
the United States
According to a report published by economists and
actuaries with the Office of the Actuary at the Centers
for Medicare and Medicaid Services (CMS)1, in 2008,
health care spending in the United States (U.S.) was
16.6% of the Gross Domestic Product (GDP).2 This
report projects that by 2018, health care spending will
amount to 20.3% of GDP — or $4.4 trillion.3
We as a nation are approaching a crossroads. Growth
in health care spending as a part of our national
economy and increasing costs and lack of affordability
are on a path towards each other at an alarming speed.
Budget shortfalls and fiscal deficits are forcing states
to redistribute funds to accommodate critical spending
needs. Data suggest that the spike in personal health
care spending is primarily attributable to rising
medical care prices, along with the effects of the 20082009 recession, an increase in Medicaid enrollment,
increasing numbers of uninsured Americans, and the
decrease in GDP experienced in 2009,4 as contributing
factors.5 The U.S. spends more than any other
developing country on health care, both in terms of per
capita spending and percentage of GDP.6 To highlight
American spending priorities, health care spending is
4.3 times greater than the amount spent on national
defense.7 While the recession has led to a deceleration
in the growth of health care spending,8 it is also
projected to cause up to thirteen million Americans
to lose their health insurance before the end of 2010.9
That also means that thousands of Americans will not
be able to pay for prescription drugs that they once
could afford under their health insurance plan.
B. Prescription Drugs
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Payment for prescription drugs is one of the most
controversial topics in the health care reform debate.
In 2004, U.S. pharmacies filled “over 3.5 billion
prescriptions.”10 In 2005, prescription drugs accounted
for ten percent of health care dollars spent, double the
5 percent of health care dollars spent in 1985, the
largest increase by far among health care spending
categories.11 Spending on prescription drugs in
2005 grew by eleven billion dollars, or 5.8%.12 In
total, in 2006, Americans spent over $216 billion on
prescription drugs.13
1. Demographics
In the next several years, the aging American population
and the rise in the proportion of seniors to working
adults will force Americans to reform regulation of
the prescription drug market to decrease the price
of prescription drugs, thereby making the drugs
affordable. The need for prescription drugs continues
to rise among people of all ages and use increases
with age.14 Between 2001 and 2004, over eighty-seven
percent of persons sixty-five and older were taking at
least one medication and almost sixty percent of the
elderly were taking three or more.15 Between 2000 and
2010, the population age sixty-five and over is expected
to rise from 34,991,753 to 40,228,712, and between
2010 and 2020, from 40,228,712 to 54,804,470.16 With
this demographic shift, and the connection between
age and use of prescription medications, the need for
prescription drugs is likely to rise.
Among those with health insurance, however, even
those age eighteen to sixty-four have had prescription
drug care delayed or have forgone purchasing
prescription drugs because of their high cost.17 Nine
percent of eighteen to sixty-four year olds delayed
or forewent prescription drug treatment due to cost
while only 5.1% of those over age sixty-five delayed
treatment and 3.6% did not get treatment.18 As the
working population reaches age sixty-five and requires
more prescription medication, those percentages will
likely rise as well.
2. Methods of Payment
The way Americans pay for prescription drugs has
also changed over the past thirty-five years. In 1970,
seventy percent of payments for prescription drugs
were private, out-of-pocket expenditures.19 By 2006,
those payments fell to twenty-five percent, while
private insurance payments for prescription drugs rose
to forty-seven percent.20 This decrease resulted from
expansion of benefits in both private health insurance
plans and government programs, including the
implementation of Medicare Part D in 2006.21 Despite
the decrease in the share of health care expenditures
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paid out-of-pocket, continuing growth in health care
costs means that consumers may continue to have
significant out-of-pocket expenditures for prescription
drugs.22
3. Price Increases
Statistics on prescription drug prices are relatively
unreliable given the number of available drugs on the
market. As of 2005, the FDA Orange Book23 contained
11,706 approved prescription drugs.24 Two studies
in particular on prescription drugs most commonly
prescribed to Medicare patients, one conducted by the
government and another by the American Association
of Retired Persons (AARP) Public Policy Institute,
show that real prices of prescription drugs subject to
the study rose significantly and outpaced consumer
prices.25
According to the study conducted in August 2005
by the Government Accountability Office (GAO)
examining trends for prescription drugs prices
reported in New York and Pennsylvania, the retail cost
to an uninsured purchaser of a thirty day supply of the
ninety-six drugs most commonly prescribed under a
large federal-worker insurance program increased by
almost twenty-five percent between January 2000 and
December 2004.26 The GAO updated the 2005 study
in 2007 for a narrower group of prescription drugs
to include data through January 2007, and found
prices for brand-name drugs in that group “increased
48.6 percent, [or] 5.8 percent average annual rate of
increase,” outpacing the Consumer Price Index (CPI)
which experienced a “9.9 percent, [or] 2.6 percent
average annual rate of increase .”27 Tracking national
drug price levels is difficult and unreliable, but the data
show price increases in two of the largest prescription
drug markets in the US over the last decade. Indeed,
more comprehensive investigation of prescription
drug prices is needed and has recently drawn support
from Congress because of the effect on government
programs.28
4. Pharmaceutical Industry Analysis
The pharmaceutical industry was the third most
profitable private industry in the U.S. in 2008 and
2009, with an almost twenty percent return of profit.29
The ten most revenue producing prescription drugs in
the U.S. in 2008 were all brand name drugs: Lipitor,
Nexium, Plavix, Advair Diskus, Seroquel, Singulair,
Enbrel, Actos, Prevacid, and Neulasta.30 About
seventy-five percent of FDA-approved prescription
drugs have generic counterparts.31 While cheaper
generics are available for brand name drugs that have

While the U.S.
government has a
history of targeting
direct and indirect
subsidies towards
particular industries,
most notoriously
agriculture, most
economists agree
that subsidies
operate less in the
interest of economic
efficiency and more
to protect domestic
industries from
foreign competition.
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lost exclusivity rights due to expiration of patents, generics are generally
not available until patent rights expire.32
Lucrative profits, favorable tax credits and provisions, and the potential
monopoly created by exclusivity in patent rights are characteristic of the
pharmaceutical industry’s astronomical rise since the 1960s.33 While the U.S.
government has a history of targeting direct and indirect subsidies towards
particular industries, most notoriously agriculture,34 most economists agree
that subsidies operate less in the interest of economic efficiency and more
to protect domestic industries from foreign competition.35 Subsidies can
help stabilize markets and raise return to investment, but such benefits
have not been proven.36 Taxpayer and consumer dissatisfaction with the
pharmaceutical industry can be traced to this mix of situational, private,
and public factors that have contributed to the pharmaceutical industry’s
prominence in the economy.37
a. A Public or Private Good?
The pharmaceutical industry is in a unique middle ground between public
goods and private industry. Prescription drugs save and improve lives.
Many Americans believe that health care is a public good. Millions of
citizens in other countries already enjoy publicly provided health care,
including publicly subsidized prescription drugs. A great number of
Americans receive prescription drugs at a government-subsidized price
through Medicare and Medicaid.
On the other hand, the prescription drug industry is, for the most part,
a private industry funded by profits that are reinvested in research and
development.38 Funds for research and development costs are the industry’s
gift and curse. A lucrative new prescription drug can yield billions of dollars
in revenue over the course of its lifetime as a brand name medication.39 Yet
for every successfully developed drug, most will fail in either research or
development, taking with them a large amount of fixed costs.40 According
to the Pharmaceutical Research and Manufacturers of America (PhRMA),
only one out of every 5000 drugs tested is eventually approved for use
by the FDA, and it takes twelve to fifteen years to develop a new drug
for market.41 The average cost of successful development of a new drug
is $800 million.42 PhRMA further estimates that only thirty percent of
drugs approved for use generate enough revenue to recoup the average
development cost.43 These costs are a product of the complicated process
of discovery or invention of new medicines, as well as FDA requirements
for new drug approval, manufacture, and distribution.44 The incentive to
research and develop with hopes of profitability is tempered by the assumed
fixed cost risk of failed research and development.45
Conversely, pharmaceutical companies justify high prices, profits, and
expenditures to the public by claiming that they develop a good that widely
improves peoples’ health. In 2009, Pfizer, the world’s largest pharmaceutical
manufacturer, stated its mission on the homepage of its company website:
At Pfizer, we’re inspired by a single goal: your health. That’s why
we’re dedicated to developing new, safe medicines to prevent and
treat the world’s most serious diseases. And why we are making them
available to the people who need them most. We believe that from
progress comes hope and the promise of a healthier world.46
It is one thing to argue that the high cost of research and development
will be redistributed from producers to consumers through high prices.
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However, it is entirely different to create an environment, especially in a
free-market economy, where producers generate limitless profits as a result
of a government sanctioned system of approval, exclusivity, and subsidy,
and consumers are given no alternative choices through restriction of
competition and parallel trade.
Moreover, the Federal Trade Commission (FTC) has documented incidents
of pharmaceutical companies attempting to distort further the market by
compensating generic drug manufacturers for delaying the introduction
of their lower cost products through patent infringement suit settlements,
known as “reverse payment” agreements.47 This conflict is separate from
the controversial FDA drug review process, in which pharmaceutical
companies under review by the FDA fund their own approval programs
through drug application user fees.48 In response to appellate court
decisions upholding settlements between brand name and generic drug
manufacturers, FTC investigators found that half of the settlements made
in 2006 and 2007 included payments from the brand name company in
exchange for a promise from the generic company to delay entry into the
market.49 The same was true for over two-thirds of the settlements between
brand name and generic companies with exclusivity rights blocking other
generic drug applicants.50 The Preserve Access to Affordable Generics Act,
introduced by Sen. Herb Kohl (D-WI) in February 2009, was proposed to
prohibit such anti-competitive agreements.51 While the bill is one measure
to protect the public from pharmaceutical companies’ underhanded
behavior, a legal and regulatory balance must still be struck between the
public good and the private market.
b. Breaking Down Expenditures
Research and development expenditures in the pharmaceutical industry are
high, and companies recoup those costs by passing them on to consumers.52
Evidence strongly suggests that, industry-wide, marketing expenditures for
drugs equal or exceed research and development expenditures.53 According
to a study by two researchers from York University, in 2004 pharmaceutical
companies spent $57.5 billion on promotion and marketing.54 According
to a National Science Foundation (NSF) report for the same year,
pharmaceutical companies spent $31.5 billion (including public funds
disbursed to the pharmaceutical industry) on domestic research and
development.55 The York University study concluded that, as a percentage
of the $235 billion in domestic prescription drug sales in 2004, promotion
and marketing expenditures accounted for twenty-four percent of each
sales dollar,56 while research and development spending accounted for
thirteen percent.57
The NSF estimates may not take into account smaller firms that are not
PhRMA members.58 These smaller firms are privately funded and driven
by research and development.59 In the traditional model, biotechnology
firms discover or develop a new drug then partner with a pharmaceutical
manufacturer who markets and promotes the medication.60 In 2003,
pharmaceutical and biotechnology firms listed on the Standard and Poor
Compustat database spent roughly sixty billion dollars on research and
development expenditures.61 Taking this estimate into account, even
at the most conservative level, including firms with high research and
development expenditures and little to no marketing expenditures in the
pharmaceutical industry, marketing and promotion costs equal or exceed
research and development.
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c. You Better Shop Around...But Can You?
The present regulatory environment surrounding U.S. pharmaceutical
manufacturing allows American prescription drug prices to be the highest
in the world. The U.S. “is the only major industrialized country in the world
that does not currently regulate prescription drug prices.”62 In 2003, the
Congressional Budget Office (CBO) estimated that, on average, foreign
prices for prescription drugs were between forty-five percent and sixty-five
percent lower than U.S. prices.63
Brand name drug costs are the primary driving factor behind the movement
to legalize drug importation from foreign countries. One notorious example
of an expensive brand name drug is Lipitor. A 20 mg tablet of Lipitor, the
top revenue producing prescription medication in the U.S. in 2008,64 sold
for four to five dollars in 2009 at CVS, the largest pharmacy chain in the
U.S.65 In several other countries, including the United Kingdom, Israel,
Canada, and New Zealand, the same prescription dosage of Lipitor sold for
anywhere from $1.32 to $2.90.66 Even where U.S. consumers try to take
advantage of lower prescription drug prices abroad, stringent regulation of
prescription drug importation for personal use prevents them from doing
so.

III. Drug Importation and Reimportation
Drug importation and reimportation policies have been proposed to
address high drug prices in the U.S. Drug importation refers to the practice
of importing prescription drugs manufactured outside of U.S. borders
into the country.67 Drug reimportation refers to the practice of importing
prescription drugs originally manufactured in the U.S. and then exported
elsewhere back into the U.S.68 The terms are often used interchangeably,
but under their precise legal definitions, mean different things.69
The Food, Drug, and Cosmetic Act70 of 1938 (FD&C Act) was passed to
“prevent the adulteration, misbranding, and false advertising of food, drugs,
devices, and cosmetics in interstate, foreign, and other commerce subject
to the jurisdiction of the U.S., for the purposes of safeguarding public
health and preventing deceit upon the purchasing public.”71 The FD&C Act
is primarily concerned with ensuring that drugs in interstate commerce,
including those that are imported or reimported, meet the FDA’s approval
process.72 In 1984, to stimulate drug development and innovation, Congress
passed the Drug Price Competition and Patent Term Restoration Act73
(popularly known as the Hatch-Waxman Act).74 The Act provided up to five
years of additional patent protection for prescription drug manufacturers to
compensate for time spent in clinical trials and awaiting FDA approval.75
The Act also allowed generic drug manufacturers to complete an abbreviated
new drug application and forego testing requirements if the generic drug
met certain equivalence standards.76
In 2000, Congress passed the Medicine Equity and Drug Safety Act77
amending the FD&C Act, to allow drug importation in an effort to reduce
medication prices.78 The statute contained an importation provision which
then Secretary of the Department of Health and Human Services (HHS),
Donna Shalala, had the authority to decertify if she determined that
implementing the provision would “pose no additional risk to the public’s
health and safety.”79 Secretary Shalala did in fact decertify the importation
provision.80
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The Pharmaceutical Market Access Act,81 first introduced in 2003 in the
House by Rep. Gil Gutknecht, was designed to amend the FD&C Act and:
(1) Give all Americans immediate relief from the outrageously high
cost of pharmaceuticals; (2) Reverse the perverse economics of the
American pharmaceutical markets; (3) Allow the importation of
drugs only if the drugs and the facilities where they are manufactured
are approved by the Food and Drug Administration, and to
exclude pharmaceutical narcotics; and (4) Require that imported
prescription drugs be packaged and shipped using counterfeitresistant technologies approved by the Bureau of Engraving and
Printing (technologies similar to those used to secure United States
currency).82
The Act would authorize the Secretary of HHS to promulgate regulations
for the importation of prescription drugs.83 Congressional findings in
support of the Act stated that:
(1) Americans unjustly pay up to 1000 percent more to fill their
prescriptions than consumers in other countries
(2) The United States is the world’s largest market for pharmaceuticals
yet consumers still pay the world’s highest prices.
(3) An unaffordable drug is neither safe nor effective. Allowing and
structuring the importation of prescription drugs ensures access
to affordable drugs, thus providing a level of safety to American
consumers they do not currently enjoy.
(4) According to the Congressional Budget Office, American seniors
alone will spend $1.8 trillion dollars on pharmaceuticals over the next
ten years.
(5) Allowing open pharmaceutical markets could save American
consumers at least $635 billion of their own money each year.84
The Act passed in the House but failed in the Senate.85
Sen. Byron Dorgan (D-ND) introduced the latest bill in the string of
congressional efforts to open U.S. borders to drug importation, the
Pharmaceutical Market Access and Drug Safety Act of 2005.86 Amendments
in the 2005 bill to Section 804 of the FD&C Act would require the Secretary
of HHS to promulgate regulations allowing “qualifying individuals” to
import prescription drug products covered under the legislation, but the bill
was never passed.87
Conversely, also in 2005, Rep. Gregory Meeks (D-NY) independently
introduced a concurrent resolution opposing legalizing personal drug
importation. 88 While the resolution was never adopted, it reiterated many
of the arguments against prescription drug importation and reimportation,
including foreign price controls, the December 2004 HHS study on
importation, the implications importation would have on the pharmacist/
patient relationship, and the lack of savings U.S. consumers would
experience if importation were legal.89 However, the final finding stated that
“[w]hereas despite significant efforts, including joint efforts with United
States Customs and Border Protection and import alerts or bulletins, the
Food and Drug Administration currently does not have sufficient resources
to ensure adequate inspection of current levels and categories of personal
shipments of prescription drugs entering the United States.”90
In an effort to include the legislation as an amendment to the current federal
health care reform bill and capitalize on political momentum surrounding
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the effort to increase access to health care and lower costs, Sen. Dorgan
proposed his bill again in December 2009.91 According to Dorgan’s
proposal, CBO estimated the bill would cut federal government costs by
$19.4 billion by 2020, and save consumers one hundred billion dollars
in the same span.92 Once again, the bill failed a floor vote,93 which was
preceded by arguments from FDA Commissioner Margaret Hamburg to
the Senate in opposition because, “as currently written,” the bill would be
“logistically challenging to implement and resource intensive” and presents
significant safety risks.94
Rep. Meeks’ resolution did not address current inadequacies in the regulatory
system. Only two statements on the price issue related to large-scale
changes. The first, placing the responsibility to lower prices on the industry,
stated that “the pharmaceutical industry and the health care community
should work to ensure that all citizens have access to prescription drugs with
the same level of safety and efficacy guaranteed under the current system
of regulation”95 (emphasis added). The second called for deregulation of
foreign price controls to encourage the flow and sale of cheaper drugs into
the U.S. for American consumers.96 Commissioner Hamburg’s two-page
letter provided no solutions to the system’s inadequacies. Prescription drug
importation and reimportation remain illegal in the U.S.97 A satisfactory
version of the bill has yet to be enacted. More importantly for the purposes
of this article, as displayed by its emphasis on the dangers of current and
potential importation, the federal government has not taken sufficient
action to address the difficulties in safely regulating illegal importation.

IV. FDA/Pharma Arguments against Importation/
Reimportation
A. Pharmaceutical Companies: Decrease in Profits Leading to Loss of
Incentive for Research and Development
The general argument justifying why brand name prescription drug costs
are highest in the U.S. is that there are extremely high fixed costs for
research and development that must be recouped in revenue to provide an
incentive for investment in future drugs.98 The fact that the industry spends
an equal or greater amount on marketing and promotions than on research
and development seriously undermines the argument that drug companies
must protect their profits from being swallowed by the importation of drugs
from countries with lower prices at the risk of losing the incentive to spend
on the future development of new drugs.99 Pharmaceutical companies
benefit from several important characteristics of the domestic market and
domestic government regulation. As previously mentioned, unlike nearly
every other industrialized nation with a pharmaceutical market, there are
no price controls on prescription drugs in the U.S.100 Second, public funds
are used for private pharmaceutical company research and development.101
Third, the pharmaceutical industry lobby is one of the largest in the
country. Finally, exclusivity through patent rights allows pharmaceutical
manufacturers to sell their products without competition. 102 Given our
country’s treatment of prescription medication as a mixed public/private
good, these protections are unparalleled in any other industry.
B. Food and Drug Administration Safety Concerns: Counterfeit, Poor
Quality, or Contaminated Drugs
The FDA and pharmaceutical companies also argue that legalized
importation would threaten to circumvent FDA standards for drug safety.103
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The FDA’s statutory responsibility is to “assure the American public that
the drug supply is safe, secure, and reliable.”104 Of primary concern to the
FDA is that the “safety and effectiveness” of drugs from outside the closed
legal and regulatory system in the U.S. cannot be ensured.105 Though there
are no reliable data on the quantity or scale of counterfeit drug operations
attempting to penetrate the U.S. border, the FDA claims that its number
of counterfeit drug investigations have quadrupled since the late 1990s.106
More recently, the rise in internet prescription drug sales and overseas
counterfeiters with sophisticated technologies and criminal backed
bankrolls have challenged the FDA to augment its efforts in securing the
closed U.S. pharmaceutical distribution system.107
In 2006, the FDA published a consumer bulletin warning against purchasing
prescription drugs from RxNorth, a company operating several websites
based in Canada.108 The investigation is ongoing. Also in 2006, several
defendants from Atlanta, Georgia, were indicted by a federal grand jury
relating to a scheme to distribute unapproved versions of Ambien, Valium,
Xanax, Cialis, Lipitor, Vioxx, and other drugs over the internet.109 The
defendants opened a facility in Belize, manufactured over twenty-four
different prescription drugs, and conspired to market the drugs through
e-mail advertisements claiming the drugs were Canadian generics.110
In 2005, a group of businesses and individuals were indicted in the
Western District of Missouri for involvement in a forty-two million dollar
conspiracy to distribute counterfeit Lipitor manufactured at a facility in
Central America and genuine Lipitor purchased in Central America.111 The
increase of large scale sophisticated counterfeiting operations, smuggling,
and internet sales reveal the greater issue — that more resources must be
expended in the regulation of prescription drugs across U.S. borders.
Information on the safety of illegally imported prescription drugs is “very
limited” — no agency of the federal government systematically collects
data on the volume of prescription drug imports.112 According to an HHS
report in December 2004, approximately ten million packages containing
prescription drugs enter the U.S. annually from all over the world.113
However, the GAO has condemned the findings as based on extrapolation
of limited data, and thus unreliable.114
The FDA is extremely under-funded, but is “doing its best to use its limited
international authorities to stop the increasing flow of violative drugs into
this country” because “the sheer volume [of illegally imported prescription
drugs] has grown to exceed the capability of FDA field personnel to
properly process.”115 To address this growing health risk, the FDA has
responded to the threats imposed by importation by “employing a riskbased enforcement strategy to target [their] existing enforcement resources
effectively in the face of multiple priorities, including homeland security,
food safety, and counterfeit drugs.”116 The current system “is already
overwhelmed by the number of incoming packages, and this presents a
significant ongoing challenge for the Agency.”117 The volume of imported
prescription drugs expected to rise suggests that the current strategy must
be significantly revamped or abandoned.

V. U.S. Regulation of Importation/Reimportation
The most influential actor in the prescription drug industry is the federal
government. Legal and regulatory protections allowing the prescription drug
market to continue operating in a closed system and generating increased
profits must be re-examined. This section will delve into the responsibilities
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and resources of federal agencies that regulate the importation of goods
into U.S. borders and compare their magnitude and effectiveness.
The FDA “coordinates with other governmental bodies and meets regularly
with other federal agencies and state officials to share information
and identify opportunities for partnering in enforcement actions.”118
U.S. Customs and Border Protection (CBP), U.S. Drug Enforcement
Administration (DEA), U.S. Immigration and Customs Enforcement (ICE)
are among the FDA’s federal agency partners.119 The FDA maintains these
relationships, among other reasons, to “leverage resources and best protect
American consumers.”120 These federal agencies all share a congressionally
delegated duty to protect our borders from harmful threats.
A. FDA Regulation of Importation
The FD&C Act authorizes the FDA to oversee the production of drugs that
meet approved standards, whether manufactured in the U.S. or abroad.121
Legally imported drugs are introduced to the U.S. market only through
FDA-approved manufacturing facilities and methods.122 The FD&C Act
outlines a list of prohibited acts that include introducing any adulterated
or misbranded food or drug into interstate commerce and causing a drug to
be a counterfeit drug, selling, dispensing, or holding for sale or dispensing
a counterfeit drug.123 Violation can result in a court ordered injunction,
or civil or criminal liability for all those who caused, aided or abetted, or
conspired in one of the prohibited acts.124 According to the FDA, by failing
to legalize prescription drug importation, Congress has concluded “that
the safety and effectiveness of imported drugs is best assured by carefully
limiting how prescription drugs can be imported in the U.S. as part of a
closed drug distribution system.”125
1. Personal Importation at Points of Entry
Under limited circumstances, an individual entering or returning to the
U.S. may personally import new prescription drugs, even those that
are unapproved, if their situation meets certain exigency standards and
documentation required by the FDA.126 According to a statement on its
website in 1998, the FDA, on its own initiative, developed guidance on
personal importation in its Regulation Procedures Manual (RPM) entitled
“Coverage of Personal Importations”.127 The purpose of the guidelines
is to provide guidance on allowing personal-use quantities of FDAapproved imported products in baggage and mail and “to gain the greatest
degree of public protection with allocated resources.”128 The importation
policy states that “because the amount of merchandise imported into the
[U.S.] in personal shipments is normally small, both in size and value,
comprehensive coverage of these imports is normally not justified.”129
The FDA has focused its enforcement priorities on commercially shipped
products, including small mail-order solicitations, which are not subject to
these RPM guidelines. They have focused “less on those products that are
personally carried, shipped by a personal non-commercial representative of
a consignee, or shipped from foreign medical facility where a person has
undergone treatment.”130
The guidelines themselves allow for significant discretion in accepting a
personal importation of an unapproved drug into the U.S. “when the quantity
and purpose are clearly for personal use, and the product does not present
an unreasonable risk to the user.”131 Stressing that RPM guidelines “are
intended only to provide operating guidance for FDA personnel and are not
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intended to create or confer any rights, privileges, or benefits on or for any
private person,” the statement goes on to describe situations where personal
importation may be allowed at FDA agents’ discretion.132 Examples
given in the guidelines include a person who has started treatment with
an unapproved drug in a foreign country, has an “ethnic background” and
prefers products from his or her homeland or labels in their native language,
or suffers from a condition for which there is no FDA-approved drug.133
In two cases, FDA personnel may act permissively in deciding whether to
allow the personal importation. In the first case, when an agent identifies
the drug’s intended use as appropriate, for example for treatment of a nonserious condition, and “the product is not known to represent a significant
health risk,” the agent may exercise wide discretion.134 In the second case,
wide discretion may be exercised where:
a) the intended use is unapproved and for a serious condition for
which effective treatment may not be available domestically either
through commercial or clinical means; b) there is no known
commercialization or promotion to persons residing in the U.S.
by those involved in the distribution of the product at issue; c) the
product is considered not to represent an unreasonable risk; and d)
the individual seeking to import the product affirms in writing that it
is for the patient’s own use (generally not more than 3 month supply)
and provides the name and address of the doctor licensed in the U.S.
responsible for his or her treatment with the product, or provides
evidence that the product is for the continuation of a treatment begun
in a foreign country.135
Should the agent have questions about any situation, the guidelines advise
him or her to hold the drug and “consult with the appropriate headquarters
office.”136
FDA personnel are instructed “not to examine personal baggage.”137 CBP
officers are responsible for examining baggage and will notify their local
FDA office when they have identified an FDA-regulated drug intended for
commercial distribution or an FDA-regulated drug that may represent a
risk to public health.138 FDA agents are responsible for regulating mail
importations, but only after CBP sets them aside following an initial
determination that they may be in violation of the FD&C Act.139
2. Importation at Mail Facilities
According to the 2004 HHS report, CBP and FDA officials at certain
mail facilities used different practices and procedures to inspect packages
containing prescription drugs.140 The basis upon which packages were
targeted varied based on several subjective and objective factors, such as the
inspector’s intuition and experience, whether packages came from suspect
countries or companies, and whether shipments were to individuals.141
While some illicit packages were inspected and seized, many others either
were not inspected and released immediately or were released after being
held for inspection.142 Because they were unable to process the volume of
packages, FDA officials released tens of thousands of packages containing
prescription drug products that could have posed a health risk to American
consumers.143
In response to the observational study on mail facilities, the FDA issued new
nationwide procedures outlining how FDA agents are to prioritize packages
for inspection, inspect the packages, and determine whether FDA-regulated
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pharmaceuticals should be allowed into the U.S. by mail.144 CBP personnel
are required to forward any mail from FDA’s national list of targeted
countries that appear to contain prescription drugs to FDA agents.145 CBP
inspectors must request and have FDA management approve a deviation
from this requirement.146 Still, related testimony before Congress revealed
that “[w]hile the new procedures should encourage processing uniformity
across facilities, many packages that contain prescription drugs are still
released,” because all packages CBP forwards to the FDA that FDA
inspectors do not process at the end of each day are returned to the U.S.
Postal Service (USPS) for delivery.147
Perhaps the most important fact in the HHS report was the finding that
there was only the equivalent of seventeen full time FDA employees whose
responsibility it was to inspect all of the international mail facilities in the
U.S. for counterfeit drugs.148 When twenty to thirty million packages enter
our borders through USPS each year, 149 this level of taxpayer resources
devoted to drug regulation in the interest of public health and safety is
completely unacceptable. Shockingly, these measures are being practiced
with the importation ban still in effect. It is estimated that more than
3.5 to 350 million U.S. prescriptions could be affected by counterfeit or
substandard drugs each year.150 As the number of prescriptions filled in
the U.S. continues to climb, a significant increase in resources allocated
to regulating importation is even more justified today than when the FDA
developed its RPM guidelines. While it may be true that implementing an
anti-counterfeit system as outlined in the Pharmaceutical Market Access
Act would not be justified in terms of a decrease in prices for American
consumers, available resources should be put towards strengthening our
nation’s current regulation of drug importation.
3. Budget Allocations
Dollar amounts and manpower allocated to the regulation of drug
importation are also telling. In the 2009 fiscal year, the FDA requested
from Congress a total budget of $2.4 billion, which includes $1.77 billion
in budget authority and $628 million in industry user fees.151 This amount
is $129.7 million more than in fiscal year 2008 budget, a 5.7% increase.152
The proposal included “strategic increases to strengthen food protection,
modernize drug safety, speed approval of generic drugs, and improve
the safety and review of medical devices.”153 Between October 2008 and
September 2009, the FDA was projected to experience a full-time equivalent
staff increase of 526 employees.154 The FY 2010 budget includes a request
for the largest increase in FDA funding history, calling for a total budget
of $3.2 billion.155 This represents a nineteen percent increase from 2009,156
and for comparison, almost four times the percentage increase from 2008
to 2009.
The FDA Human Drugs Program (HDP) is authorized to ensure that
prescription, generic, and over-the-counter (OTC) drug products are
adequately available to the public and are safe and effective.157 The HDP is
responsible for monitoring drug products for unexpected health risks and for
enforcing the quality of drug products.158 The HDP received roughly $777
million for its total budget in 2009 and requested $908 million in 2010.159
The HDP operates with assistance from the FDA Office of Regulatory
Affairs (ORA), which provides leadership on import and inspection
policies.160 In 2009, the ORA received $725 million for its total budget,
a roughly twelve percent increase over 2008.161 Through its field offices,
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ORA supports the HDP by conducting domestic and foreign inspections
of drug manufacturers to assess their compliance with manufacturing
standards and investigating incidents of product tampering that may affect
FDA-regulated goods.162
Where criminal activity is involved, ORA’s Office of Criminal Investigations
(OCI) complements the ORA Field Drug Program (FDP).163 Both
appropriations and user fees fund the FDP.164 The amount allocated to the
FDP in the 2010 budget request is just under $145 million and supports 763
full time employees, an increase of roughly twenty-seven million dollars
and sixty-four employees over 2009.165
The 2009 allocation to the FDP included funding for an initiative targeting
post-manufacture prescription drug safety by monitoring imported
prescription drugs.166 Designed to combat an FDA estimated twelve
percent increase in the volume of imported pharmaceutical drugs in 2009,
the funding increase was designed to allow the FDP to “support three
new agents to investigate criminal drug import violations.”167 Thus, of the
expected increase of 526 new full time FDA staff, only three will have the
responsibility of investigating criminal importation.
Fortunately, in both criminal and civilian drug importation cases, ORA
coordinates import activities with CBP. However, the FDA explicitly
acknowledges in its budget documents that security concerns and the
increase in the number of imports make the task of regulation difficult with
the current amount of resources the FDA receives.168 In fiscal year 2010, the
FDA projects a total of 20.5 million import lines, two percent (or 410,000)
of which will be human drugs and biologic products.169 That is hardly
an acceptable workload for so few personnel. Such a meager increase,
combined with the assignment of three new field agents, is an unreasonable
response to a problem the FDA acknowledges is growing exponentially.
Notably, the budget includes five million dollars for “the FDA to develop
policies to allow Americans to buy drugs approved in other countries.”170
While this is a step in the direction of acknowledging importation as a
possible solution, the budget makes no explicit mention of a related full
time employee increase, and within the budget justification there is only
one explanation of what development will take place. 171 In 2010, of the
five million dollars dedicated to developing import policies generally,
only one million dollars is allocated to the FDP,172 a disappointing number
considering the historic increase and the need to improve effectiveness of
any effort to strengthen current importation enforcement policy.173
B. U.S. Customs and Border Protection Regulation
The FDA and the CBP work together on several fronts to examine products
entering U.S. borders, protect the American public from foreign health risks,
and enforce the laws of the U.S. against illegal activity and international
threats.174 On March 1, 2003, all immigration inspectors, agricultural
border inspectors, and the border patrol merged with U.S. Customs to form
the U.S. Customs and Border Protection agency within DHS.175 There are
now four agencies within DHS charged with securing U.S. borders: CBP,
the Bureau of Immigration and Customs Enforcement (ICE), the U.S.
Coast Guard, and the Transportation Security Administration (TSA).176
The merger was part of both Title VI of the Customs Modernization Act
(also known as the Mod Act), 177 enacted as part of NAFTA implementing
legislation in 1993, and the Homeland Security Act of 2002.178 With the
creation of CBP, all arms of the federal government with significant border
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enforcement responsibilities were unified into one agency for the first time
in U.S. history.179

and a policy response not only from government agencies but also from
legislators and the President to reform drug regulation.

1. CBP by the Numbers

One positive example of CBP and FDA joint operations shows that
increased coordination between the agencies in terms of both manpower
and technology can be fruitful. Pursuant to an agreement between CBP
and the FDA, the FDA is allowed to commission CBP officers to assist the
FDA with examination and investigation of food imports when importers
provide prior notice of importation as part of the Bioterrorism Act.194
The agreement also requires that the FDA provide appropriate training to
commissioned CBP inspectors, provide twenty-four hour assistance to CBP,
reimburse CBP for costs associated with examination and investigation,
share information, and jointly develop additional agreements to implement
the agreement’s purpose.195 In addition to providing FDA with manpower,
CBP is required to collect samples for analysis, or analyze samples
themselves, to detect illegitimate food imports.196

In 2008, there were over 19,726 U.S. Customs inspectors and canine
enforcement officers.180 In fiscal year 2008, CBP inspectors logged more
than thirty million entries of commercial imports.181 To fund its growing
operations, CBP’s budget request for fiscal year 2009 represented an
increase of $1.66 billion, or 17.9% over 2008, and totals $10.94 billion —
$1.45 billion of which was to be collected through user fees.182 In contrast,
the 2008 budget request represented a nine percent increase over fiscal
year 2007.183 The only highlight in the CBP 2008 fiscal year in review
statement relating to consumer import safety states that CBP “established
a dedicated import safety branch and worked closely with other federal
agencies to protect the American public from unsafe . . . imported products.
CBP collocated [sic] Consumer Product Safety Commission personnel at
several of our ports of entry to improve targeting and information sharing
between the agencies.”184
2. Proposed CBP Policies
In a 2005 report to Congress, the GAO made several recommendations to
the various agencies responsible for regulating prescription drug imports.185
The overarching idea was to require a CBP task force involving ICE, FDA,
USPS, DEA, and the Office of National Drug Control Policy to develop a
strategic framework to help formulate policy reforms.186 First, the GAO
recommended that the task force establish an approach for estimating
the scope of the prescription drug problem, particularly the volume of
drugs entering the country through mail and carrier facilities.187 Second,
to estimate the scope of the problem, the task force would gauge results
by establishing objectives, milestones, and performance measures and a
methodology to gauge results.188 Third, the task force would determine
the resources needed to address the flow of illegally imported prescription
drugs and where those resources should be targeted.189 Fourth, the task
force would evaluate progress, identify barriers to achieving goals, and
suggest modifications to the current regulatory system.190 As a final and
unrelated suggestion, the GAO recommended that the Secretary of HHS
re-examine and provide a report on removing or modifying the requirement
that the FDA must allow personal importers the opportunity to provide
documentation that their prescription drugs are legitimate.191
Implementation of these recommendations is ongoing, but has yet to be
fully achieved. For example, in response to the second recommendation,
CBP claimed it had developed a document that contains a mission statement,
outlines the responsibilities of the various agencies, and presents objectives,
milestones, and performance measures.192 According to the GAO, however,
the CBP document does not: establish concrete milestones including target
dates by which tasks should be completed, outline performance measures
that CBP and other agencies can use to gauge performance and results,
or show what resources are needed to address the problem and where
resources should be targeted.193 While the recommendations did not give
detailed instructions, four years is not an unreasonable time to allow a
federal agency to work in conjunction with other agencies and develop
documents to address an increasing problem. Because the FDA claims it
faces a higher incidence of unapproved drugs entering U.S. borders with
no additional funding, there must be both a greater sense of urgency
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Again, data are difficult to collect on the effectiveness of measures involving
import interdiction. Training border personnel in multiple areas of regulation
is one cost-effective method of increasing the federal government’s ability
to regulate imports. By having agents who are independently capable of
examining, investigating, and detaining goods that they determine may be
illicit, counterfeit, or a health risk, the FDA will better be able to make use
of limited resources. Placing more efficient FDA or CBP personnel on the
frontlines could lower costs in the long run and create high-skilled jobs.
C. TSA Regulation of Commercial Air Travel
Congress created the TSA in response to the September 11, 2001 terrorist
attacks and charged the DHS agency with protecting U.S. air and ground
transportation to ensure freedom of movement for people and goods.197
Under authority of the Aviation and Transportation Security Act, the TSA
established a baggage screener workforce and took over the responsibility of
screening domestic commercial air passengers and bags from commercial
air carriers. 198 CBP remains responsible for screening international
commercial air travelers.
The TSA’s budget request for fiscal year 2009 was $7.1 billion, a total
increase of $286 million over the fiscal year 2008.199 Of the total amount
requested, $5.3 billion went toward aviation security.200 Beginning as a
relatively small agency, the TSA now employs over 50,000 people.201 The
TSA provides a valuable example of effective hiring and training measures
for inspections agents to increase manpower. In building its workforce
essentially from the bottom up, TSA began by hiring and training the first
federal screeners, known as Transportation Security Officers (TSOs) in
airports and charged them with stopping simple prohibited items including
razors and firearms.202 TSOs are now “highly-trained, multi-skilled”
agents that perform physical and behavioral screening using sophisticated
screening equipment throughout airports nationwide.203
In 2006, TSA screened 708,400,522 people through airport security,
535,020,271 individual pieces of checked luggage, and opened and
examined 85,571,710 bags for prohibited items.204 The TSA attributes
its effectiveness in training and retaining TSOs to a number of initiatives,
including: career development, attrition reduction, and workplace safety
measures.205 In particular, to address inadequacies in field offices, TSA
requires field offices to maintain a Model Workplace Program to improve
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their employees’ work environment. This has reduced full-time attrition
from 13.6% in 2004 to 11.6% in 2007 and part-time attrition from 57.8%
in 2004 to 37.2% in 2007.206 The TSA also changed its centralized hiring
process to the local airport level, reducing hiring cost per TSO by over
thirty-six percent from 2004 to 2007.207

VI. Reforms
Drug importation and reimportation may be an adequate solution to
the problem of escalating and unaffordable prescription drug prices.
Regardless of whether importation is the answer, there are existing issues
within the FDA that must be addressed to solve current inadequacies in
drug regulation.
In theory, government funding is a finite resource which must be
appropriated to agencies and programs in a manner commensurate with
their importance to and effectiveness at addressing problems. Looking at
the resources the government applies to certain government measures in
relation to others should provide the American people, both with an idea
of what problems the government currently finds most pressing and how
pressing those problems are as determined by the amount of funding they
receive. Furthermore, with the current rate at which the government is
spending on economic stimulus,208 there are plenty of funds available if
the government deems a problem to be urgent enough for the well-being
of the nation.
A safe supply of prescription drugs is a legitimate government interest, as
are safe commercial air travel and the safety of all imported products. In the
absence of accurate data on the incidence of unsafe or counterfeit goods, 209
determining how many resources should be funneled is largely a subjective
exercise. To the American people, prescription drugs, which accounted
for over $216 billion in sales in 2008,210 are an incredibly important and
growing expense as the population continues to age.211
Breaches in border safety are incredibly difficult to measure because there
are no methods to gauge how many illicit goods go undetected.212 Gauging
the magnitude of the prescription drug problem is difficult because drugs
can be imported through the mail or carried across the border.213 As the
GAO recommended to the CBP, creating a network or database to accurately
determine how many illicit prescription drugs enter U.S. borders should be
the first step.214
The FDA is inhibited by three factors in the battle against unapproved,
unsafe, or counterfeit prescription drugs: lack of adequate funding, lack of
adequate manpower, and inefficient processes.215 There are several lessons
the government can take from other measures used in regulation of people
and products at our borders. While DHS, CBP, and TSA are not perfect,
each presents a valuable method the FDA could adopt in increasing its
abilities to combat safety issues in prescription drug importation.
1. Funding
Lack of funding is at the top of the list of FDA deficiencies. The FY 2009
FDA budget request was a 5.7% increase over fiscal year 2008 budget,216
a relatively small increase in comparison to the 2009 CBP request, which
jumped 17.9% over 2008.217 The TSA’s budget request for fiscal year 2009
was $7.1 billion, a total increase of $286 million over fiscal year 2008 that
more closely resembles the FDA’s relative increase from 2008.218 Of the
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total amount requested, seventy-five percent went toward Aviation Security,
one program within the TSA.219
Although it is difficult to compare funding measures of these three agencies
because of differences in the number of incidences of total examinations
and inspections — up to fifty million for the FDA, eighty-five million for
the TSA, and thirty million for CBP220 — there have almost certainly been
more incidences of illegal importation of goods, including prescription
drugs, than there have been terrorist threats on aircrafts in the U.S. since
2008.221 This is not an argument that the TSA should receive less funding,
but there must be a more proportionate amount of funding to the level and
magnitude of the risk at issue. The one million dollar budget allocation
to the FDP for development of a drug importation user fee is especially
disappointing.222 If FDA concerns for drug safety are so pressing, more
funding must be allocated. While the 2010 funding increase is a landmark
step,223 it remains to be seen how far that step will go toward actually
increasing enforcement of drug safety.
2. Manpower
FDA manpower and efficient use of that manpower must also be increased.
While the FDA has greatly expanded its hiring of scientists, doctors and
statisticians since 2007,224 field agents must become a priority. Physical
examination is the only current method available to seize unsafe prescription
drugs at import points of entry.225 Between October 2008 and September
2009, the FDA was to experience a full-time equivalent staff increase of
526 and of those, only three new agents were to be hired to investigate
criminal drug import violations as part of the FDA’s FDP (there was no
mention of an increase in the number of agents responsible for investigating
personal importation).226
This issue provides a chance for the government to create highly skilled
jobs in a time when many government agencies, especially those dedicated
to security, are understaffed. Agreements like the one between CBP and
the FDA on commissioning and training agents in multiple disciplines
are a good starting point in addressing the lack of personnel available to
process the massive amount of imports.227 The problem must be addressed
at different levels. Implementing new hiring practices at the local level
in individual mail facilities and improving retention to eliminate hiring
costs, as the TSA has done,228 would be an excellent starting point to cut
administrative costs while creating jobs.
Job creation must be part of the equation to solve the problem of inadequate
manpower. For example, the number of full time FDA personnel examining
all drug imports at international mail facilities around the country must be
increased from seventeen.229 Such a number is completely unacceptable.
The result, that at one facility roughly 10,000 packages a week are returned
to USPS for delivery, is equally unacceptable.230 At least some FDA
personnel should be positioned onsite, rather than stationed in the field
office and called to the mail facility when a USPS or CBP agent determines
a package should be held.231
3. Processes
To ensure that adequate funding and sufficient manpower are put to
productive use, the FDA and other agencies involved must formulate a plan
to address the importation dilemma that includes more efficient processes.
First, the GAO recommendations to CBP must be completed.232 Since 2005,
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none of the four recommendations the GAO proposed have been adequately
met.233 Five years is far too long to fail to achieve a basic framework for
developing new policies. Congress, especially those proponents of personal
prescription drug importation, must push these agencies to complete the
task.
On the enforcement level, the FDA and CBP must put in place more
effective procedures for inspection of personal drug importation. The FDA
has focused its enforcement efforts on commercial rather than personal
shipments because the value and size of those imports do not justify a
more complete inspection process.234 This argument is entirely resourcebased and shifts the focus away from the FDA’s concern about consumer
product safety. As mentioned above, the system is in need of restructuring
or abandonment235 combined with an increase in available agents to
inspect both commercial and personal shipments at adequate levels. When
this article was submitted for publication, FDA Commissioner Hamburg
announced that in 2010, the FDA would begin using an improved riskbased database, the PREDICT system, to replace its current import
documentation database.236 Implementation of the PREDICT system
shows that the FDA has sought methods to improve the inspection process.
It will be interesting to see how PREDICT improves FDA’s ability to detect
illicit imported prescription drugs.237
In practice, a determination for importation is a judgment that must be
made quickly. Risk-based database tracking, due to the varying nature of
regulation of international mail,238 cannot target the continuing problem
of lack of resources allocated to international mail facilities. The FDA has
yet to propose a solution to this problem (perhaps there is no systematic
solution), but the lack of sufficient manpower is evident.239 As for personal
importation policy, in the interest of pragmatism, allowing agents a
significant amount of discretion in the RPM guidelines is good policy
because of the subjective nature of the inquiry.240 Though “we cannot
inspect our way to safety,”241 agencies can improve methods and augment
the ability to meet the increasing numbers of illicit imported prescription
drugs.

VII. Conclusion
Why are we as a society so unwilling to devote the necessary resources to
devise and implement quality control measures in an industry like health
care, where quality services and pharmaceuticals are the only means of
survival for millions of Americans? We as a nation are at a crossroads. The
depth of the current economic recession increases the likelihood that the
American people will demand health care reform at a greater pace than
governments are currently undertaking. Though the FDA claims safety
cannot be assured if personal importation is legal, it cannot effectively
regulate the current in flow of prescription drugs through international mail,
commercial shipment, or consumer importation at border points of entry.
The FDA and CBP must establish a method to gauge the magnitude of the
problem. They have failed in this regard. No measures for improvement will
be possible or effective until the degree of the problem can be understood.
Funding, manpower, and processes must be reformed to address the
current inadequacies in prescription drug regulation. Increased funding,
job creation, multi-disciplinary training, and on-site personnel are possible
answers to the problems.
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The amount of prescription drugs entering the U.S has increased
substantially in the past twenty years and will undoubtedly continue to
increase in the foreseeable future.242 Market forces will force America
to fundamentally change how we regulate the pharmaceutical industry,
prescription drug prices, and the safety of imported drugs. Drug importation
and reimportation may very well be an adequate solution to the problem of
escalating and unaffordable prescription drug prices. Regardless of whether
importation is the answer, we must put our money where our mouth is and
address existing issues to solve current inadequacies in imported drug
regulation.
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